Scarica l'app Stockscreener
9.00
10.00%
-1.00
Pre-mercato:
8.99
-0.010
-0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$10.00
Aprire:
$9.45
Volume 24 ore:
32.91M
Relative Volume:
0.99
Capitalizzazione di mercato:
$9.25B
Reddito:
$113.29M
Utile/perdita netta:
$-351.47M
Rapporto P/E:
-23.09
EPS:
-0.3898
Flusso di cassa netto:
$-309.19M
1 W Prestazione:
-5.66%
1M Prestazione:
+53.06%
6M Prestazione:
+276.57%
1 anno Prestazione:
+198.01%
Intervallo 1D:
$8.93
$9.60
Intervallo di 1 settimana:
$8.83
$10.98
Portata 52W:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
9.00 | 10.28B | 113.29M | -351.47M | -309.19M | -0.3898 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Immunitybio Inc Borsa (IBRX) Ultime notizie
Piper Sandler Maintains Overweight on ImmunityBio (IBRX) March 2026 - Meyka
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
ImmunityBio Shares Retreat Despite Strong Commercial Momentum - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Stock Price Down 10.2%What's Next? - MarketBeat
ImmunityBio Director’s Share Sale Spurs Investigations: Stock Faces Downturn - timothysykes.com
IMMUNITYBIO, INC. (IBRX) Stock, Price, News, Quotes, Forecast and Insights - MSN
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth - The Chronicle-Journal
ImmunityBio (NASDAQ:IBRX) Shares Gap DownTime to Sell? - MarketBeat
Major Director Share Sale Hits ImmunityBio Stock - StocksToTrade
ImmunityBio (IBRX) Shares Drop Nearly 10% as Investors Digest Recent Earnings - International Business Times AU
ImmunityBio Faces Increased Investor Skepticism Amid Recent Developments - timothysykes.com
ImmunityBio: Advancing ANKTIVA Into a Global, Multi-Indication Immunotherapy Platform Supporting a Buy Rating and $15 Target - TipRanks
Piper Sandler raises Immunitybio stock price target on revenue growth - Investing.com
IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside - Stocktwits
ImmunityBio, Inc. (IBRX) Price Target Raised After Strong ANKTIVA Launch - Insider Monkey
ImmunityBio (IBRX) Is Down 13.4% After ANKTIVA Data And New EMEA DealsWhat's Changed - simplywall.st
IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions - Stocktwits
ImmunityBio Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: ImmunityBio’s Q4 2025 EPS beats forecast, stock surges - Investing.com
IBRX: 700% revenue growth and global expansion highlight a transformational year for ANKTIVA - TradingView
ImmunityBio (NASDAQ:IBRX) Shares Down 4.2%Should You Sell? - MarketBeat
ImmunityBio, Inc. (IBRX) Stock Analysis: A Biotech Powerhouse With 29% Upside Potential - DirectorsTalk Interviews
ImmunityBio (IBRX) stock wobbles in premarket ahead of update call — what traders are watching - TechStock²
Citigroup Inc. Decreases Stake in ImmunityBio, Inc. $IBRX - MarketBeat
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook - Stocktwits
A Look At ImmunityBio (IBRX) Valuation After ANKTIVA Trial Progress And New Regulatory Milestones - simplywall.st
ImmunityBio (NASDAQ:IBRX) Trading 6.7% Higher Following Better-Than-Expected Earnings - MarketBeat
ImmunityBio Target of Unusually High Options Trading (NASDAQ:IBRX) - MarketBeat
ImmunityBio Surges After European Approval Boosts ANKTIVA’s Global Reach - StocksToTrade
ImmunityBio Advances Chemotherapy Free Immunotherapies And Faces Key Investor Tests - Sahm
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 - marketscreener.com
ImmunityBio, Inc. (IBRX) Competitors - Meyka
IBRX (ImmunityBio) pre-market: Q4 2025 results Mar 3, 2026 could move stock - Meyka
IBRX Earnings History & Surprises | EPS & Revenue Results | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend - Stocktwits
Special Edition: Why Can’t We Cure Cancer? A National Conversation | Full CUOMO Show 2/27 - ImmunityBio
ImmunityBio Stock Pre-Market (+6.5%): Phase 2 Trial Enrollment Completed Early - Trefis
ImmunityBio (NASDAQ:IBRX) Shares Up 2.4%Still a Buy? - MarketBeat
Key facts: ImmunityBio completes Phase 2 trial enrollment; conference call set - TradingView
Promising Biotech Stocks To ConsiderFebruary 27th - MarketBeat
IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds - Stocktwits
ImmunityBio Trial Progress Puts Anktiva’s Global Cancer Potential in Focus - Yahoo Finance
IBRX Stock Price, Forecast & Analysis | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
ImmunityBio (NASDAQ:IBRX) Director Sells $900,750.00 in Stock - MarketBeat
Simon, director, sells ImmunityBio (IBRX) shares worth $900k - Investing.com
ImmunityBio Director Sells 75,000 Shares - TradingView
Assessing ImmunityBio (IBRX) Valuation After Trial Progress And Strong Anktiva Commercial Momentum - Yahoo Finance
ImmunityBio Inc Trade Ideas — LSX:A2QQ2E - TradingView
ImmunityBio (IBRX) soars to new high on Anktiva future expansion - MSN
ImmunityBio Grapples with Allegations as Stock Tumbles - timothysykes.com
ImmunityBio (IBRX) loses 17% to profit-taking after intra-day high - MSN
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):